Publishing research using ab137132? Please let us know so that we can cite the reference in this datasheet.

ab137132 has been referenced in 26 publications.

  • Liu S  et al. Tumor microenvironment classification based on T-cell infiltration and PD-L1 in patients with mismatch repair-proficient and -deficient colorectal cancer. Oncol Lett 17:2335-2343 (2019). PubMed: 30675299
  • Naruse T  et al. Immunohistochemical Study of PD-1/PD-L1 Axis Expression in Oral Tongue Squamous Cell Carcinomas: Effect of Neoadjuvant Chemotherapy on Local Recurrence. Pathol Oncol Res N/A:N/A (2019). PubMed: 30767115
  • Meng Y  et al. PD-L1 Expression Correlates With Tumor Infiltrating Lymphocytes And Response To Neoadjuvant Chemotherapy In Cervical Cancer. J Cancer 9:2938-2945 (2018). PubMed: 30123362
  • Guo Y  et al. Immune checkpoint inhibitor PD-1 pathway is down-regulated in synovium at various stages of rheumatoid arthritis disease progression. PLoS One 13:e0192704 (2018). PubMed: 29489833
  • Sun C  et al. Oncofetal gene SALL4 reactivation by hepatitis B virus counteracts miR-200c in PD-L1-induced T cell exhaustion. Nat Commun 9:1241 (2018). PubMed: 29593314
  • Du S  et al. Blockade of Tumor-Expressed PD-1 promotes lung cancer growth. Oncoimmunology 7:e1408747 (2018). PubMed: 29632720
  • Drakes ML  et al. Stratification of ovarian tumor pathology by expression of programmed cell death-1 (PD-1) and PD-ligand- 1 (PD-L1) in ovarian cancer. J Ovarian Res 11:43 (2018). PubMed: 29843813
  • Gao J  et al. VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer. Nat Med 23:551-555 (2017). PubMed: 28346412
  • Qin Y  et al. Parallel profiling of immune infiltrate subsets in uveal melanoma versus cutaneous melanoma unveils similarities and differences: A pilot study. Oncoimmunology 6:e1321187 (2017). IHC ; Human . PubMed: 28680759
  • Zheng Z  et al. Hepatitis C virus mediated chronic inflammation and tumorigenesis in the humanised immune system and liver mouse model. PLoS One 12:e0184127 (2017). PubMed: 28886065
  • Ahn H  et al. Clinicopathologic implications of the miR-197/PD-L1 axis in oral squamous cell carcinoma. Oncotarget 8:66178-66194 (2017). PubMed: 29029502
  • Ma K  et al. PD-L1 and PD-1 expression correlate with prognosis in extrahepatic cholangiocarcinoma. Oncol Lett 14:250-256 (2017). PubMed: 28693161
  • Imai D  et al. The prognostic impact of programmed cell death ligand 1 and human leukocyte antigen class I in pancreatic cancer. Cancer Med 6:1614-1626 (2017). IHC-P ; Human . PubMed: 28602029
  • Zhou ZH  et al. The prognostic value and pathobiological significance of Glasgow microenvironment score in gastric cancer. J Cancer Res Clin Oncol N/A:N/A (2017). IHC ; Human . PubMed: 28180998
  • Ring KL  et al. Potential immunotherapy targets in recurrent cervical cancer. Gynecol Oncol N/A:N/A (2017). IHC ; Human . PubMed: 28233576
  • Fan Y  et al. Prognostic value of PD-L1 and PD-1 expression in pulmonary neuroendocrine tumors. Onco Targets Ther 9:6075-6082 (2016). IHC ; Human . PubMed: 27785054
  • Kim JW  et al. Prognostic implications of immunosuppressive protein expression in tumors as well as immune cell infiltration within the tumor microenvironment in gastric cancer. Gastric Cancer 19:42-52 (2016). IHC ; Human . PubMed: 25424150
  • Ji M  et al. PD-1/PD-L1 expression in non-small-cell lung cancer and its correlation with EGFR/KRAS mutations. Cancer Biol Ther N/A:0 (2016). IHC ; Human . PubMed: 26954523
  • Chen PL  et al. Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade. Cancer Discov N/A:N/A (2016). PubMed: 27301722
  • Shi LZ  et al. Interdependent IL-7 and IFN-? signalling in T-cell controls tumour eradication by combined a-CTLA-4+a-PD-1 therapy. Nat Commun 7:12335 (2016). IHC-P ; Human . PubMed: 27498556
  • Zou MX  et al. Expression of programmed death-1 ligand (PD-L1) in tumor-infiltrating lymphocytes is associated with favorable spinal chordoma prognosis. Am J Transl Res 8:3274-87 (2016). IHC-P ; Human . PubMed: 27508049
  • Li Y  et al. Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer. Mol Cancer 15:55 (2016). IHC-P ; Human . PubMed: 27552968
  • Cooper ZA  et al. Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma. Oncoimmunology 5:e1136044 (2016). IHC-P ; Human . PubMed: 27141370
  • Antonios JP  et al. PD-1 blockade enhances the vaccination-induced immune response in glioma. JCI Insight 1:N/A (2016). PubMed: 27453950
  • Feldmeyer L  et al. Density, Distribution, and Composition of Immune Infiltrates Correlate with Survival in Merkel Cell Carcinoma. Clin Cancer Res 22:5553-5563 (2016). PubMed: 27166398
  • Lim YJ  et al. High ratio of programmed cell death protein 1 (PD-1)(+)/CD8(+) tumor-infiltrating lymphocytes identifies a poor prognostic subset of extrahepatic bile duct cancer undergoing surgery plus adjuvant chemoradiotherapy. Radiother Oncol 117:165-70 (2015). IHC-P ; Human . PubMed: 26235847

For licensing inquiries, please contact

Sign up